The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Desmoid tumors, though benign, are locally aggressive with tendril-like growths causing pain, limited range of motion and even impaired mobility. (SpringWorks) SpringWorks Therapeutics is launching a ...
STAMFORD, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced ...
Word of the potential acquisition comes as SpringWorks awaits an FDA approval decision on its MEK inhibitor mirdametinib toward the end of February. (AndreyPopov ...
SpringWorks Therapeutics received FDA approval for its oral gamma secretase inhibitor Ogsiveo, for the treatment of adult patients with desmoid tumors. The approval is based on positive results from ...
Presented positive topline data from the pivotal Phase 2b ReNeu trial evaluating mirdametinib, an investigational oral MEK inhibitor, in pediatric and adult patients with neurofibromatosis type ...
Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of SWTX's ...
NEW YORK--(BUSINESS WIRE)--SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its ...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.--(BUSINESS WIRE)--MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE ...
Investment merits have increased materially since my last article with more support for its approved therapy and pipeline advancements. Ample liquidity supports its operations and pipeline development ...
SpringWorks Therapeutics, Inc. SWTX expanded its existing clinical collaboration agreement with GSK GSK. The partnership is evaluating the combination of SpringWorks’ investigational oral gamma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results